This phase II trial studies how well stereotactic radiosurgery before tumor resection works in treating patients with tumors that have spread to the brain from another place in the body. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and cause less damage to normal tissue.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02514915.
PRIMARY OBJECTIVE:
I. To determine the efficacy of giving pre-operative radiosurgery to patients pending resection of a brain metastasis.
SECONDARY OBJECTIVES:
I. To evaluate overall survival.
II. To evaluate distant intracranial failure associated with this therapy.
III. To evaluate the Health Related Quality of Life (HRQL) associated with this therapy.
EXPLORATORY OBJECTIVE:
I. To collect and store the resected body tissue(s) and blood samples for potential correlation to clinical outcome.
OUTLINE:
Patients undergo SRS over 1 hour and 1-7 days later patients undergo surgical resection of tumor.
After completion of study treatment, patients are followed up at 10-14 days, every 3 months for 12 months, then every 4 months for 2 years.
Lead OrganizationUPMC-Shadyside Hospital
Principal InvestigatorChristopher Wilke
